PDF herunterladen
Aktuelle Ernährungsmedizin 2012; 37(S 01): S30-S33
DOI: 10.1055/s-0031-1298858
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Das geheime Leiden

Reizdarm als Folge mangelnder DarmgesundheitSuffering in SilenceIrritable Bowel Syndrome as the Consequence of Lacking Gut Health
R. Meier
Kantonsspital Liestal, Medizinische Universitätsklinik
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. März 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Der Reizdarm ist eine häufig auftretende funktionelle Erkrankung, deren Pathogenese nicht im Detail geklärt ist. Es zeichnet sich jedoch ab, dass neben anderen Faktoren auch die intestinalen Bakterien involviert sind. Die Zusammensetzung weist bei Reizdarmpatienten deutliche Verschiebungen im Vergleich zu Gesunden auf. Bei einem Teil der Patienten kann eine geringgradige Entzündung in der Darmwand nachgewiesen werden, die vermutlich auf der veränderten Zusammensetzung der Bakterien basiert. Lokal im Darm wirksame Antibiotika sowie Probiotika tragen zur Korrektur der gestörten Balance der Bakterien bei und reduzieren wahrscheinlich neben anderen Mechanismen die entzündliche Aktivität. Metaanalysen zufolge können einige ausgewählte Probiotika zu einer Verbesserung der Reizdarmsymptome führen. Allerdings ist die Wirkung der Probiotika stammspezifisch. In verschiedenen Studien erwiesen sich nur bestimmte Keime als wirksam, andere zeigten keine Effekte. Probiotika bieten interessante Ansätze zur Verbesserung von Reizdarmsymptomen und werden in der Praxis zunehmend eingesetzt.

Abstract

Irritable bowel syndrome is a common functional disorder whose pathogenesis is not exactly known. However, it is becoming obvious that in addition to other factors, the intestinal bacteria are involved. The bacterial composition is notably different in patients with irritable bowel syndrome compared with healthy subjects. In a proportion of patients, low-grade inflammation of the intestinal wall is found, which is suspected to be caused by the changed bacterial composition. Antibiotics that are locally effective in the gut, as well as probiotics, contribute to correcting the bacterial dysbalance and, in addition to other mechanisms, probably reduce the inflammatory activity. Meta-analyses have shown that selected probiotics may improve the symptoms of irritable bowel syndrome. However, the effect of the probiotics depends on the specific bacterial strain. Various studies have shown that certain strains were effective, whereas others did not show any effect. Probiotics offer interesting approaches to improving the symptoms of irritable bowel syndrome and are increasingly used in practice.

Schlüsselwörter

intestinale Bakterien - Dysbalance - Entzündung - Antibiotika - Probiotika - abdomineller Bauchumfang - Reizdarmbeschwerden

Keywords

intestinal bacteria - dysbalance - inflammation - antibiotics - probiotics - abdominal circumference - irritable bowel syndrome
 

  • Literatur

  • 1 Drossman DA, Camilleri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2831
    CrossrefPubMedGoogle Scholar
  • 2 Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005; 34: 189-204
    CrossrefPubMedGoogle Scholar
  • 3 Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: the functional gastrointestinal disorders. 3rd. ed. McLean, VA: Degnon; 2006: 487-555
    Google Scholar
  • 4 Saito YA, Cremonini F, Talley NJ. Association of the 1438G/A and 102T/C polymorphism of the 5-HT2A receptor gene with irritable bowel syndrome 5-HT2A gene polymorphism in irritable bowel syndrome. J Clin Gastroenterol 2005; 39: 835 author reply 835–836
    PubMedGoogle Scholar
  • 5 Mertz H, Naliboff B, Munakata J et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52
    CrossrefPubMedGoogle Scholar
  • 6 Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 2009; 19: 141-150, vii
    CrossrefPubMedGoogle Scholar
  • 7 Posserud I, Stotzer PO, Bjornsson ES et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 802-808
    CrossrefPubMedGoogle Scholar
  • 8 Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33
    CrossrefPubMedGoogle Scholar
  • 9 Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007; 19: 166-172
    CrossrefPubMedGoogle Scholar
  • 10 Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007; 42 (Suppl. 17) 41-47
    CrossrefPubMedGoogle Scholar
  • 11 Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-858
    CrossrefPubMedGoogle Scholar
  • 12 Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382
    CrossrefPubMedGoogle Scholar
  • 13 Brint EK, MacSharry J, Fanning A et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-336
    CrossrefPubMedGoogle Scholar
  • 14 Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783
    CrossrefPubMedGoogle Scholar
  • 15 Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920
    CrossrefPubMedGoogle Scholar
  • 16 O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
    CrossrefPubMedGoogle Scholar
  • 17 Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 6; 364: 22-32
    PubMedGoogle Scholar
  • 18 Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-563
    CrossrefPubMedGoogle Scholar
  • 19 Gribar SC, Richardson WM, Sodhi CP et al. No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation. Mol Med 2008; 14: 645-659
    PubMedGoogle Scholar
  • 20 Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005; 54: 1182-1193 Epub 2005 Apr 19
    CrossrefPubMedGoogle Scholar
  • 21 Sherman PM, Ossa JC, Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr Clin Pract 2009; 24: 10-14
    CrossrefPubMedGoogle Scholar
  • 22 Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine. Curr Opin Gastroenterol 2004; 20: 82-88
    CrossrefPubMedGoogle Scholar
  • 23 Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277: 50959-50965
    CrossrefPubMedGoogle Scholar
  • 24 Madsen K, Jijon H, Yeung H et al. DNA from probiotic bacteria exerts antiinflammatory actions on intestinal epithelial cells by inhibition of NF-kappa B. Gastroenterology 2002; 122: A64
    PubMedGoogle Scholar
  • 25 Kelly D, Campbell JI, King TP et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004; 5: 104-112 Epub 2003 Dec 21
    CrossrefPubMedGoogle Scholar
  • 26 Peña JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol 2003; 5: 277-285
    CrossrefPubMedGoogle Scholar
  • 27 Haller D, Serrant P, Peruisseau G et al. IL-10 producing CD14 low monocytes inhibit lymphocyte-dependent activation of intestinal epithelial cells by commensal bacteria. Microbiol Immunol 2002; 46: 195-205
    PubMedGoogle Scholar
  • 28 Petrof E, Kojima K, Ropeleski MJ et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004; 127: 1474-1487
    CrossrefPubMedGoogle Scholar
  • 29 Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2008; 59: 325-332
    PubMedGoogle Scholar
  • 30 McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-2661
    CrossrefPubMedGoogle Scholar
  • 31 Agrawal A, Houghton LA, Morris J et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 29: 104-114
    PubMedGoogle Scholar
  • 32 Marteau P, Cuillerier E, Meance S et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002; 16: 587-593
    CrossrefPubMedGoogle Scholar
  • 33 Bouvier M, Méance S, Bouley C et al. Effects of consumption of a milk fermented by a probiotic Bifidobacterium animalis (strain DN-173-010) on colonic transit times in healthy humans. Biosci Microflora 2001; 20: 43-48
    PubMedGoogle Scholar
  • 34 Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-486
    CrossrefPubMedGoogle Scholar
  • 35 Guyonnet D, Woodcock A, Stefani B et al. Fermented milk containing Bifidobacterium lactis DN-173 010 improved self-reported digestive comfort amongst a general population of adults. A randomized, open-label, controlled, pilot study. J Dig Dis 2009; 10: 61-70
    CrossrefPubMedGoogle Scholar
  • 36 Guyonnet D, Schlumberger A, Mhamdi L et al. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 2009; 102: 1654-1662
    CrossrefPubMedGoogle Scholar
  • 37 Layer P, Andersen V, Pehl C et al. DGVS-Leitlinie Reizdarm. Z Gastroenterol 2011; 49: 237-293
    Google Scholar
  • 38 Shanahan F. Probiotics in perspectives. Gastroenterology 2010; 139: 1808-1812
    CrossrefPubMedGoogle Scholar